2,6-dichloro-7,8-dihydro-6H-quinolin-5-one | 1028330-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,6-dichloro-7,8-dihydro-6H-quinolin-5-one
• 英文别名: 2,4-dichloro-7,8-dihydroquinolin-5(6H)-one；2,4-dichloro-7,8-dihydro-6H-quinolin-5-one
• CAS: 1028330-50-8
• 化学式: C₉H₇Cl₂NO
• 分子量: 216.067
• InChiKey: CSRAYLSWTFMAPH-UHFFFAOYSA-N

物化性质

• 沸点：
  365.5±42.0 °C(Predicted)
• 密度：
  1.441±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-7,8-dihydro-6H-quinolin-5-one 在 四(三苯基膦)钯 、 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.0h， 生成 4-cyclopropyl-5-oxo-5,6,7,8-tetrahydroquinoline-2-carbonitrile
  参考文献：
  名称：

  三环类化合物及其制备方法和应用

  摘要：

  本发明公开了三环类化合物及其在药物中的应用，具体地，本发明涉及一类新型的三环类化合物以及包含该类化合物的药物组合物。本发明还涉及所述化合物的制备方法，以及所述化合物或药物组合物在制备治疗GPR84拮抗剂介导的疾病和/或病症的药物中的用途，特别是在制备治疗非酒精性脂肪肝病、炎症性肠病、特发性肺纤维化和糖尿病神经痛的药物中的用途。

  公开号：

  WO2024140968A1
• 作为产物：
  描述：

  2,4,6-三氯苯基马来酸二酯 、 3-氨基-2-环己烯-1-酮 在 三氯氧磷 作用下， 以 溴苯 为溶剂， 反应 4.5h， 以30%的产率得到2,6-dichloro-7,8-dihydro-6H-quinolin-5-one
  参考文献：
  名称：

  SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF

  摘要：

  揭示了含有5,6,7,8-四氢喹啉衍生物的C5a受体调节剂、含有这些衍生物的组合物，以及它们用于预防和治疗疾病和症状的方法，包括但不限于免疫和炎症性疾病和症状。

  公开号：

  US20090048295A1

文献信息

• SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Barbay Joseph Kent

  公开号：US20090048295A1

  公开（公告）日：2009-02-19

  Substituted 5,6,7,8-tetrahydroquinoline derivatives, which are C5 a receptor modulators, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, immune and inflammatory diseases and conditions, are disclosed.

  揭示了含有5,6,7,8-四氢喹啉衍生物的C5a受体调节剂、含有这些衍生物的组合物，以及它们用于预防和治疗疾病和症状的方法，包括但不限于免疫和炎症性疾病和症状。
• Design and optimization of aniline-substituted tetrahydroquinoline C5a receptor antagonists
  作者：Yong Gong、J. Kent Barbay、Mieke Buntinx、Jian Li、Jean Van Wauwe、Concha Claes、Guy Van Lommen、Pamela J. Hornby、Wei He

  DOI：10.1016/j.bmcl.2008.06.059

  日期：2008.7

  A series of aniline-substituted tetrahydroquinoline C5a receptor antagonists were discovered. A functionality requirement of ortho substitution on the aniline was revealed. Secondary anilines, in general, outperformed tertiary analogs in inhibition of C5a-induced calcium mobilization. Further enhancement of activity was realized in the presence of an ortho hydroxyalkyl side chain. The functional IC(50) of selected analogs was optimized to the single-digit nanomolar level. (C) 2008 Elsevier Ltd. All rights reserved.
• [EN] SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDROQUINOLÉINES SUBSTITUÉES, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009023669A1

  公开（公告）日：2009-02-19

  Substituted 5,6,7,8-tetrahydroquinoline derivatives, which are C5a receptor modulators, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, immune and inflammatory diseases and conditions, are disclosed.
• 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
  申请人：[en]THE CLEVELAND CLINIC FOUNDATION

  公开号：WO2023250480A1

  公开（公告）日：2023-12-28

  Disclosed herein are compounds that inhibit the function of 3β-hydroxysteroid dehydrogenase (3βHSD1), pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., for the treatment of prostate cancer, breast cancer, and other diseases dependent on the activity of 3βHSD1.
• Synthesis and characterization of 5,6,7,8-tetrahydroquinoline C5a receptor antagonists
  作者：J. Kent Barbay、Yong Gong、Mieke Buntinx、Jian Li、Concha Claes、Pamela J. Hornby、Guy Van Lommen、Jean Van Wauwe、Wei He

  DOI：10.1016/j.bmcl.2008.03.049

  日期：2008.4

  A novel series of substituted 2-aryl-5-amino-5,6,7,8-tetrahydroquinoline C5a receptor antagonists is reported. Synthetic routes were developed that allow the substituents on the tetrahydroquinoline core to be efficiently varied, facilitating determination of structure-activity relationships. Members of the series display high binding affinity for the C5a receptor and are potent functional antagonists. (c) 2008 Elsevier Ltd. All rights reserved.